PepGen Inc.: PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments

- Phase 2 open-label CONNECT1-EDO51 study expected to be initiated in Canada in the first half of 2023 - - Potentially registration-directed, randomized, double-blind, placebo-controlled Phase 2 CONNECT2-EDO51

Related Keywords

United States ,Boston ,Massachusetts ,Canada ,American ,Sarah Sutton ,Laurence Watts ,James Mcarthur ,Nasdaq ,Muscular Dystrophy Association Clinical Scientific Conference ,Gilmartin Group ,Pepgen Inc ,American Academy Of Neurology ,Enhanced Delivery Oligonucleotide ,Dystrophy Association Clinical ,American Academy ,Three Months Ended March ,Private Securities Litigation Reform Act ,Consolidated Statements ,Gefallene Big Techs ,Pepgen ,Reports ,First ,Quarter ,023 ,Financial ,Results ,Ecent ,Corporate ,Developments ,